ETR:MOR MorphoSys (MOR) Stock Price, News & Analysis → Like Tiny Crypto Retirement Funds (From Crypto 101 Media) (Ad) Free MOR Stock Alerts €66.40 0.00 (0.00%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range€65.82▼€66.6450-Day Range€30.75▼€66.4052-Week Range€13.45▼€66.58Volume173,645 shsAverage Volume153,687 shsMarket Capitalization$2.50 billionP/E Ratio24.78Dividend Yield1.26%Price TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get MorphoSys alerts: Email Address Ad Porter & CompanyThe world’s greatest investmentI believe this could change your life forever. I’m talking about transforming everything for you, financially. You see, a rare market anomaly has emerged that I believe is going to make some people very wealthy. Almost nobody in the mainstream media or Wall Street has connected the dots on what’s going on, but that ignorance won’t last for long. When they wake up to this situation, billions of dollars will flood in.Click here now to sign up About MorphoSys Stock (ETR:MOR)MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule to treat myelofibrosis; Felzartamab, an antibody directed against CD38 for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule to promote anti-tumor activity by inhibiting EZH2 and EZH1. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases; and Otilimab, an antibody for rheumatoid arthritis. The company has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Read More MOR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOR Stock News HeadlinesMarch 15, 2024 | finance.yahoo.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 13, 2024 | markets.businessinsider.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 19, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 13, 2024 | benzinga.comMorphoSys: Q4 Earnings InsightsMarch 12, 2024 | msn.comGerman regulators approve Novartis deal to buy drugmaker MorphosysFebruary 15, 2024 | finance.yahoo.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 8, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreFebruary 7, 2024 | realmoney.thestreet.comMorphoSys just downgraded at JMP Securities, here's whyMarch 19, 2024 | Weiss Ratings (Ad)The ONE AI sSock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …February 6, 2024 | finance.yahoo.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | seekingalpha.comNovartis And MorphoSys Are A Perfect MatchFebruary 5, 2024 | finance.yahoo.comNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashFebruary 5, 2024 | finance.yahoo.comUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnFebruary 3, 2024 | morningstar.comMorphoSys AG ADR MORJanuary 31, 2024 | markets.businessinsider.comDAX Edges Higher As Investors Await GDP DataJanuary 30, 2024 | marketwatch.comUS Futures Flat, European Stocks Slightly Down Ahead of Central Bank DecisionsJanuary 30, 2024 | markets.businessinsider.comEuropean Shares Slightly Higher; Flash Eurozone GDP Data AwaitedJanuary 30, 2024 | msn.comMorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M rangeJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 18, 2024 | seekingalpha.comMorphoSys: Positive Pelabresib Data Finally Unlocking UpsideJanuary 8, 2024 | markets.businessinsider.comEQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2024 | finance.yahoo.comMorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2023 | finance.yahoo.comOptimistic Investors Push MorphoSys AG (ETR:MOR) Shares Up 48% But Growth Is LackingDecember 14, 2023 | markets.businessinsider.comMorphoSys To Issue 3.423 Mln New Shares At EUR 30/shrDecember 14, 2023 | marketwatch.comMorphoSys Shares Fall After Raising Funds to Accelerate Drug Launch, TrialsDecember 13, 2023 | markets.businessinsider.comEQS-Adhoc: Ad hoc: MorphoSys AG Launches Cash Capital Increase by way of Accelerated Bookbuilding ProcessSee More Headlines Receive MOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeETR SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolETR:MOR CUSIPN/A CIKN/A Webwww.morphosys.de Phone+49-89-899270FaxN/AEmployees544Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)€2.68 Trailing P/E Ratio24.78 Forward P/E Ratio328.01 P/E Growth0.06Net Income$91.45 million Net Margins35.06% Pretax MarginN/A Return on Equity4,188.87% Return on Assets-5.68% Debt Debt-to-Equity Ratio887.68 Current Ratio3.14 Quick Ratio3.49 Sales & Book Value Annual Sales$260.86 million Price / Sales9.57 Cash Flow€128.09 per share Price / Cash Flow0.52 Book Value(€1.96) per share Price / Book-33.88Miscellaneous Outstanding Shares37,600,000Free FloatN/AMarket Cap$2.50 billion OptionableNot Optionable Beta0.61 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Jean-Paul Kress M.D. (Age 59)Chairman of Management Board, MD & CEO Comp: $2.03MDr. Lucinda Crabtree Ph.D. (Age 45)CFO & Member of Management Board Ms. Charlotte Lohmann (Age 54)Chief Legal and Human Resources Officer & Member of Management Board Mr. Klaus De WallHead of Accounting & TaxDr. Margit UrbanHead of Discovery Alliances & TechnologiesDr. Julia Neugebauer Ph.D.Head of Investor RelationsDr. Barbara Krebs-Pohl Ph.D.Chief Business OfficerDr. Günter WellnhoferHead of Technical OperationsDr. Ralf OstendorpHead of Protein Sciences & CMCDr. Harald WatzkaHead of Alliance ManagementMore ExecutivesKey CompetitorsBiotest AktiengesellschaftETR:BIOEvotecETR:EVTShop Apotheke EuropeETR:SAECompuGroup Medical SE & Co. KGaAETR:COPGerresheimerETR:GXIView All Competitors MOR Stock Analysis - Frequently Asked Questions How have MOR shares performed in 2024? MorphoSys' stock was trading at €34.00 at the start of the year. Since then, MOR stock has increased by 95.3% and is now trading at €66.40. View the best growth stocks for 2024 here. What other stocks do shareholders of MorphoSys own? Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Gilead Sciences (GILD), SolarEdge Technologies (SEDG), Supernus Pharmaceuticals (SUPN), AbbVie (ABBV), Abbott Laboratories (ABT), MercadoLibre (MELI), Neurocrine Biosciences (NBIX), Nightstar Therapeutics (NITE) and NVIDIA (NVDA). This page (ETR:MOR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThe world’s greatest investmentPorter & CompanySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders Agency Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.